Patient characteristics and outcome
| UPN . | Age . | Sex . | Disease . | Disease state . | Stem cell source . | Conditioning . | Outcome . |
|---|---|---|---|---|---|---|---|
| 623 | 38 | F | AML | PR | HLA-id fam | TBI/CTX | Alive, CR |
| 626 | 51 | M | AML | PR | HLA-id fam | TBI/CTX | Dead, relapse |
| 627 | 44 | M | AML | second CR | Mism fam | TBI/CTX | Alive, CR |
| 651 | 26 | F | AML | PR | Haplo-id fam | TBI/TT/CTX | Dead, toxicity |
| 656 | 49 | M | AML | second CR | HLA-id fam | TBI/CTX | Alive, CR |
| 660 | 35 | F | AML | second CR | MUD | TBI/CTX | Dead, toxicity |
| 664 | 33 | F | AML | PR | Haplo-id fam | TBI/TT/CTX | Alive, CR |
| 686 | 19 | F | AML | first CR | Autologous | TBI/CTX | Alive, CR |
| 689 | 59 | M | AML | PR | HLA-id fam | Bu/CTX | Dead, relapse |
| 696 | 40 | F | Secondary AML | first CR | MUD | TBI/CTX | Alive, CR |
| 697 | 51 | M | AML | first CR | Autologous | TBI/CTX | Dead, relapse |
| 698 | 47 | F | Secondary AML | PR | Mism fam | TBI/CTX | Alive, CR |
| 706 | 51 | M | AML | PR | Haplo-id fam | TBI/TT/CTX | Dead, toxicity |
| 709 | 60 | F | Secondary AML | PR | HLA-id fam | Bu/CTX | Alive, CR |
| 711 | 41 | M | AML | first CR | Autologous | TBI/CTX | Alive, CR* |
| 715 | 45 | M | AML | first CR | HLA-id fam | TBI/CTX | Dead, relapse |
| 717 | 47 | M | MDS | NC | HLA-id fam | TBI/CTX | Alive, CR |
| 718 | 55 | F | MDS | RAEB-T | HLA-id fam | Bu/CTX | Alive, CR |
| 729 | 50 | M | AML | PR | MUD | TBI/CTX | Dead, relapse |
| 732 | 36 | M | AML | first CR | HLA-id fam | TBI/CTX | Alive, CR |
| 733 | 23 | M | AML | PR | HLA-id fam | TBI/CTX | Dead, toxicity |
| 738 | 17 | M | AML | PR | HLA-id fam | TBI/CTX | Alive, CR |
| 740 | 57 | F | AML | first CR | Syngeneic | Bu/CTX | Alive, CR |
| 742 | 43 | M | AML | PR | MUD | TBI/CTX | Dead, relapse |
| 744 | 63 | M | MDS | RAEB-T | HLA-id fam | Bu/CTX | Dead, toxicity |
| 748 | 46 | M | MDS | NC | MUD | TBI/CTX | Dead, relapse |
| 749 | 45 | M | AML | PR | MUD | TBI/CTX | Dead, relapse |
| 754 | 60 | F | AML | second CR | Autologous | Bu/CTX | Alive, CR |
| 757 | 38 | M | AML | second CR | HLA-id fam | TBI/CTX | Alive, CR |
| 764 | 32 | F | AML | PR | MUD | TBI/CTX | Dead, toxicity |
| 784 | 59 | F | AML | first CR | HLA-id fam | Bu/CTX | Alive, CR |
| 788 | 33 | F | AML | first CR | MUD | TBI/CTX | Alive, CR |
| 795 | 33 | F | AML | PR | Haplo-id fam | TBI/TT/CTX | Dead, toxicity |
| 803 | 47 | F | Secondary AML | PR | MUD | TBI/CTX | Dead, toxicity |
| 807 | 50 | F | Secondary AML | PR | HLA-id fam | Bu/CTX | Alive, CR |
| 811 | 53 | F | AML | second CR | MUD | Bu/CTX | Alive, CR |
| UPN . | Age . | Sex . | Disease . | Disease state . | Stem cell source . | Conditioning . | Outcome . |
|---|---|---|---|---|---|---|---|
| 623 | 38 | F | AML | PR | HLA-id fam | TBI/CTX | Alive, CR |
| 626 | 51 | M | AML | PR | HLA-id fam | TBI/CTX | Dead, relapse |
| 627 | 44 | M | AML | second CR | Mism fam | TBI/CTX | Alive, CR |
| 651 | 26 | F | AML | PR | Haplo-id fam | TBI/TT/CTX | Dead, toxicity |
| 656 | 49 | M | AML | second CR | HLA-id fam | TBI/CTX | Alive, CR |
| 660 | 35 | F | AML | second CR | MUD | TBI/CTX | Dead, toxicity |
| 664 | 33 | F | AML | PR | Haplo-id fam | TBI/TT/CTX | Alive, CR |
| 686 | 19 | F | AML | first CR | Autologous | TBI/CTX | Alive, CR |
| 689 | 59 | M | AML | PR | HLA-id fam | Bu/CTX | Dead, relapse |
| 696 | 40 | F | Secondary AML | first CR | MUD | TBI/CTX | Alive, CR |
| 697 | 51 | M | AML | first CR | Autologous | TBI/CTX | Dead, relapse |
| 698 | 47 | F | Secondary AML | PR | Mism fam | TBI/CTX | Alive, CR |
| 706 | 51 | M | AML | PR | Haplo-id fam | TBI/TT/CTX | Dead, toxicity |
| 709 | 60 | F | Secondary AML | PR | HLA-id fam | Bu/CTX | Alive, CR |
| 711 | 41 | M | AML | first CR | Autologous | TBI/CTX | Alive, CR* |
| 715 | 45 | M | AML | first CR | HLA-id fam | TBI/CTX | Dead, relapse |
| 717 | 47 | M | MDS | NC | HLA-id fam | TBI/CTX | Alive, CR |
| 718 | 55 | F | MDS | RAEB-T | HLA-id fam | Bu/CTX | Alive, CR |
| 729 | 50 | M | AML | PR | MUD | TBI/CTX | Dead, relapse |
| 732 | 36 | M | AML | first CR | HLA-id fam | TBI/CTX | Alive, CR |
| 733 | 23 | M | AML | PR | HLA-id fam | TBI/CTX | Dead, toxicity |
| 738 | 17 | M | AML | PR | HLA-id fam | TBI/CTX | Alive, CR |
| 740 | 57 | F | AML | first CR | Syngeneic | Bu/CTX | Alive, CR |
| 742 | 43 | M | AML | PR | MUD | TBI/CTX | Dead, relapse |
| 744 | 63 | M | MDS | RAEB-T | HLA-id fam | Bu/CTX | Dead, toxicity |
| 748 | 46 | M | MDS | NC | MUD | TBI/CTX | Dead, relapse |
| 749 | 45 | M | AML | PR | MUD | TBI/CTX | Dead, relapse |
| 754 | 60 | F | AML | second CR | Autologous | Bu/CTX | Alive, CR |
| 757 | 38 | M | AML | second CR | HLA-id fam | TBI/CTX | Alive, CR |
| 764 | 32 | F | AML | PR | MUD | TBI/CTX | Dead, toxicity |
| 784 | 59 | F | AML | first CR | HLA-id fam | Bu/CTX | Alive, CR |
| 788 | 33 | F | AML | first CR | MUD | TBI/CTX | Alive, CR |
| 795 | 33 | F | AML | PR | Haplo-id fam | TBI/TT/CTX | Dead, toxicity |
| 803 | 47 | F | Secondary AML | PR | MUD | TBI/CTX | Dead, toxicity |
| 807 | 50 | F | Secondary AML | PR | HLA-id fam | Bu/CTX | Alive, CR |
| 811 | 53 | F | AML | second CR | MUD | Bu/CTX | Alive, CR |
UPN indicates unique patient number; AML, acute myeloid leukemia; PR, partial remission; HLA-id fam, HLA-identical family donor; TBI/TT/CTX, 6 × 2 Gy + 10 mg/kg thiotepa + 120 mg/kg cyclophosphamide; CR, complete remission; Mism fam, mismatched family donor; Haplo-id fam, haploidentical family donor; MUD, matched unrelated donor; Bu, busulfan; MDS, myelodysplastic syndrome; NC, not classifiable.
After MUD transplant.